A biotechnology company focused on human infectious & neglected diseases in Africa, LatAm and the Caribbean that works within a complete ecosystem to go from research to market

  • Developing a diversified pipeline (that includes 6 candidates for a 2nd Generation COVID 19 Vaccine) and agile structure streamlined to de-risk early stage development
  • Flexible R&D platform based on recombinant viral vector technologies, such as adenovirus, AAV, and lentivirus, capable of developing a broad set of products
  • Strong partner network to efficiently run preclinical and clinical trials, with years of combined tea experience working together in a diverse set of projects
  • One of few teams in the region that covers all the way from basic science to serving local markets